746 related articles for article (PubMed ID: 18311582)
41. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
42. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
[TBL] [Abstract][Full Text] [Related]
43. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
44. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
45. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
46. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
[TBL] [Abstract][Full Text] [Related]
47. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
Span PN; Lindberg RL; Manders P; Tjan-Heijnen VC; Heuvel JJ; Beex LV; Sweep CG
J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
[TBL] [Abstract][Full Text] [Related]
48. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
49. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
Lash TL; Gurwitz JH; Silliman RA
J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
[TBL] [Abstract][Full Text] [Related]
50. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
51. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
Ciocca DR; Green S; Elledge RM; Clark GM; Pugh R; Ravdin P; Lew D; Martino S; Osborne CK
Clin Cancer Res; 1998 May; 4(5):1263-6. PubMed ID: 9607585
[TBL] [Abstract][Full Text] [Related]
52. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
53. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
54. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
55. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
56. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
[TBL] [Abstract][Full Text] [Related]
57. Clinical validation of a customized multiple signature microarray for breast cancer.
Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
[TBL] [Abstract][Full Text] [Related]
58. Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure.
Fles R; Hoogendoorn WE; Platteel I; Scheerman CE; de Leeuw-Mantel G; Mourits MJ; Hollema H; van Leeuwen FE; van Boven HH; Nederlof PM
Genes Chromosomes Cancer; 2010 Aug; 49(8):699-710. PubMed ID: 20544844
[TBL] [Abstract][Full Text] [Related]
59. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
60. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer.
Ghosh MG; Thompson DA; Weigel RJ
Cancer Res; 2000 Nov; 60(22):6367-75. PubMed ID: 11103799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
